Stem cell therapy for ischemic heart diseases
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Introduction: Ischemic heart diseases, especially the myocardial infarction, is a major hazard problem to human health. Despite substantial advances in control of risk factors and therapies with drugs and interventions including bypass surgery and stent placement, the ischemic heart diseases usually result in heart failure (HF), which could aggravate social burden and increase the mortality rate. The current therapeutic methods to treat HF stay at delaying the disease progression without repair and regeneration of the damaged myocardium. While heart transplantation is the only effective therapy for end-stage patients, limited supply of donor heart makes it impossible to meet the substantial demand from patients with HF. Stem cell-based transplantation is one of the most promising treatment for the damaged myocardial tissue. Sources of data: Key recent published literatures and ClinicalTrials.gov. Areas of agreement: Stem cell-based therapy is a promising strategy for the damaged myocardial tissue. Different kinds of stem cells have their advantages for treatment of Ischemic heart diseases. Areas of controversy: The efficacy and potency of cell therapies vary significantly from trial to trial; some clinical trials did not show benefit. Diverged effects of cell therapy could be affected by cell types, sources, delivery methods, dose and their mechanisms by which delivered cells exert their effects. Growing points: Understanding the origin of the regenerated cardiomyocytes, exploring the therapeutic effects of stem cell-derived exosomes and using the cell reprogram technology to improve the efficacy of cell therapy for cardiovascular diseases. Areas timely for developing research: Recently, stem cell-derived exosomes emerge as a critical player in paracrine mechanism of stem cell-based therapy. It is promising to exploit exosomes-based cell-free therapy for ischemic heart diseases in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Myocyte Turnover in the Aging Human Heart
Kajstura, J., Gurusamy, N., Ogórek, B., Goichberg, P., Clavo-Rondon, C., Hosoda, T., D'Amario, D., Bardelli, S., Beltrami, A. P., Cesselli, D., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.231498 · Cited by 287
RetractedInduced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 3×
“In addition, it is reported that iPSCs are similar with ESCs in morphology, proliferation, telomerase activities, feeder dependence, epigenetic status, surface markers, gene expression, formation of embryonic bodies in vitro, promoter activities and teratoma formation in vivo; and the iPS cell culture condition is ide…”
BackgroundIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 2×
“Furthermore, these cells express various of endothelial markers and can incorporate into neovessels at injured sites, and were named as endothelial progenitor cells (EPCs).(66) EPCs seem to be a mixed population of cells originating from hybrid progenitor cells within the bone marrow or exist at different stages of en…”
BackgroundMultilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies
Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001) · Tissue Engineering · doi:10.1089/107632701300062859 · Cited by 7,956
Hydrogels for biomedical applications
Hoffman, A. S. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00239-3 · Cited by 4,864
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Evidence for Cardiomyocyte Renewal in Humans
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabé-Heider, F., Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H., et al. (2009) · Science · doi:10.1126/science.1164680 · Cited by 3,130
Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells
Rehman, J., Traktuev, D., Li, J., Merfeld-Clauss, S., Temm-Grove, C. J., Bovenkerk, J. E., Pell, C. L., Johnstone, B. H., Considine, R. V., & March, K. L. (2004) · Circulation · doi:10.1161/01.cir.0000121425.42966.f1 · Cited by 2,269
Gnecchi, M., He, H., Liang, O. D., Melo, L. G., Morello, F., Mu, H., Noiseux, N., Zhang, L., Pratt, R. E., Ingwall, J. S., et al. (2005) · Nature Medicine · doi:10.1038/nm0405-367 · Cited by 1,677
Cardiomyocyte Grafting for Cardiac Repair: Graft Cell Death and Anti-Death Strategies
Zhang, M., Methot, D., Poppa, V., Fujio, Y., Walsh, K., & Murry, C. E. (2001) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.2001.1367 · Cited by 878
Metadata
- Authors
- Yu, H., Lu, K., Zhu, J., & Wang, J.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-01-01
- Volume
- 121
- Issue
- 1
- Pages
- 135-154
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2584531832
- Cited by
- 159
- References
- 13
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stem cell therapy for ischemic heart diseases. https://app.cochat.ai/papers/10.1093/bmb/ldw059
- The paper
- Yu, H., Lu, K., Zhu, J., & Wang, J. (2017). Stem cell therapy for ischemic heart diseases. British Medical Bulletin. https://doi.org/10.1093/bmb/ldw059
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.